Strategic Imperatives
1.1 Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth
1.2 The Strategic Imperative 8™
1.3 The Impact of the Top Three Strategic Imperatives in theObstructive Lung Disease Management Industry
1.4 Growth Opportunities Fuel the Growth Pipeline Engine™
Research Context and Summary of Findings
2.1 Research Context

2.2 Research Coverage and Key Questions
2.3 Research Methodology
2.4 Key Findings in the Obstructive Lung Disease Management Landscape
2.5 Increased Risks in COVID-19 Patients
Obstructive Lung Disease Management - Current Therapies and Challenges
3.1 Unmet Medical Needs for Obstructive Lung Disease Management
3.2 Challenges in Existing Therapeutics for COPD
3.3 Challenges in Existing Therapeutics for Asthma and Cystic Fibrosis
3.4 New Efforts to Address Challenges
3.5 Therapies to Address Challenges
Obstructive Lung Disease Management - Therapeutics in Development
4.1 Biologics
4.1.1 Biologics - Key Developments
4.2 Small Molecules
4.2.1 Small Molecules - Key Developments
4.3 Gene Therapy
4.3.1 Gene Therapy - Key Developments
4.4 RNA Therapy
4.4.1 RNA Therapy - Key Developments
4.5 Stem Cell Therapy
4.5.1 Stem Cell Therapy - Key Developments
4.6 Combination Therapy
4.6.1 Combination Therapy - Key Developments
4.7 Clinical Trials and Classification by Modality
4.8 Technology Adoption and Research Impact
4.8 Technology Adoption and Research Impact (continued)
Obstructive Lung Disease Management - Designing New Delivery Systems
5.1 Advancements in Drug Delivery Systems for Targeting and Stability
5.2 New Approaches in Targeted Delivery Systems
5.3 Types of Nanoparticle-based Delivery Systems
Obstructive Lung Disease Management - IP, Commercialization, Funding, and Regional Trends
6.1 Patent Landscape for Obstructive Lung Disease Management
6.2 Patent Classification by Modality
6.3 Top Patents in Screening Patients Technology

Future Management of Respiratory Diseases
7.1 Increased Adoption of Digital and Smart Technologies
7.2 Overcoming Adherence Challenges with Smart Inhalers
7.3 Key Developments and Participants
7.4 Collaborations for Smart Technologies Adoption
Key Companies
8.1 NuvoAir
8.2 Adherium
8.3 OmniSpirant
8.4 Synairgen
8.5 Eloxx Pharmaceuticals
8.6 Regeneron Pharmaceuticals
Growth Opportunity Universe
9.1 Growth Opportunity 1: Developing a Suitable Environment for Global Adoption of Smart Technologies

9.2 Growth Opportunity 2: Increasing Collaborations Between Start-Ups and Big Pharma Companies to Develop RNA Therapeutics

9.3 Growth Opportunity 3: Improving Delivery Strategies and Formulations through Partnerships

1Appendix
10.1 Asthma - Phase III Clinical Trials

10.1 Asthma - Phase III Clinical Trials (continued)
10.2 Cystic Fibrosis - Phase III Clinical Trials
10.3 COPD - Phase III Clinical Trials
1Key Industry Influencers
11.1 Industry Interactions

1Next Steps
12.1 Your Next Steps
12.2 Why Frost, Why Now?
Legal Disclaimer